Results 221 to 230 of about 21,604,258 (289)

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

open access: yesHLA
Schenk HCM   +8 more
europepmc   +1 more source

CAR‐HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B‐cell non‐Hodgkin lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar   +9 more
wiley   +1 more source

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

open access: yesBlood Cancer J
Sharp J   +13 more
europepmc   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

A real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently ...
Victor Tellez   +12 more
wiley   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy